特立帕肽更新。

Teriparitide update.

机构信息

Cedars-Sinai Bone Center of Excellence, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA.

出版信息

Rheum Dis Clin North Am. 2011 Aug;37(3):471-7, vii. doi: 10.1016/j.rdc.2011.08.002.

DOI:10.1016/j.rdc.2011.08.002

PMID:22023903

Abstract

Teriparitide (TPD) is a novel anabolic agent that stimulates bone formation. TPD reduces risk of vertebral and nonvertebral fracture. Due to its positive effects on bone formation, many new uses of TPD are being explored. It has been studied and approved for glucocorticoid-induced osteoporosis. Many questions about the use of TPD remain including use of follow-up therapy, combination therapy, sequential therapy, and its potential role in fracture healing and treatment of back pain related to osteoporosis.

摘要

特立帕肽（TPD）是一种新型的促合成代谢药物，可刺激骨形成。TPD 可降低椎体和非椎体骨折的风险。由于其对骨形成的积极作用，目前正在探索 TPD 的许多新用途。它已被研究并批准用于治疗糖皮质激素诱导的骨质疏松症。关于 TPD 的使用仍有许多问题有待探讨，包括后续治疗的使用、联合治疗、序贯治疗，以及它在骨折愈合和治疗与骨质疏松症相关的背痛方面的潜在作用。